Oral abrocitinib in the treatment of granuloma annulare: a case report

Abstract

Aim: To evaluate the therapeutic efficacy and safety of JAK inhibitor abrocitinib in patients with localized granuloma annulare (GA) and to review the available cases documented in English.

Methods: We presented a patient who had a persistent, localized granuloma anulare (GA) for one year and did not respond to traditional therapies. This patient was treated with oral abrocitinib at a dosage of 150 mg daily.

Results: After 6 weeks of treatment with abrocitinib, the patient exhibited notable symptom improvement with no new lesions. No adverse events or recurrences were reported during the 5-month follow-up period.

Conclusions: Abrocitinib may be a promising and safe treatment option for patients with localized GA who do not respond to traditional therapies.

Keywords:

• Granuloma annulare
• JAK inhibitors
• abrocitinib

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was supported by Guangzhou Basic Research Plan Jointly Funded by the City, School (Hospital), and/or Enterprise (Grant No.2023A03J0472); the Medical Science and Technology Research Foundation of Guangdong Province (Grant No. A2022052).